Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regulus Therapeutics

8.22
+0.11001.36%
Post-market: 8.18-0.0390-0.47%18:23 EDT
Volume:1.16M
Turnover:9.49M
Market Cap:569.10M
PE:-11.36
High:8.28
Open:8.20
Low:8.07
Close:8.11
Loading ...

Wells Fargo Downgrades Regulus Therapeutics to Equalweight From Overweight, $9 Price Target

MT Newswires Live
·
01 May

Regulus Therapeutics Cut to Hold From Buy by Jones Trading

Dow Jones
·
01 May

Regulus Therapeutics Cut to Hold From Buy by Canaccord Genuity

Dow Jones
·
01 May

Top Midday Gainers

MT Newswires Live
·
01 May

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

Dow Jones
·
01 May

S&P 500 Falls 2%; Caterpillar Reports Downbeat Q1 Results

Benzinga
·
30 Apr

Novartis to Buy Regulus Therapeutics for up to $1.7 Billion

Reuters
·
30 Apr

Regulus downgraded to Hold from Buy at Canaccord

TIPRANKS
·
30 Apr

Regulus Shares Jump 134% to $7.88 After Novartis Agrees to Buy Co for up to $1.7 Bln

THOMSON REUTERS
·
30 Apr

BRIEF-Regulus Therapeutics Upon Termination Of Merger Deal Under Some Circumstances, Co To Pay Parent Termination Fee Of $27.3 Million

Reuters
·
30 Apr

Regulus Therapeutics: Upon Termination of Merger Deal Under Some Circumstances, Co to Pay Parent Termination Fee of $27.3 Mln

THOMSON REUTERS
·
30 Apr

BUZZ-Regulus Therapeutics' stock price doubles on Novartis's buyout offer

Reuters
·
30 Apr

Novartis to Acquire Regulus in $1.7B Deal

Dow Jones
·
30 Apr

Shares of Regulus Therapeutics Jump 130% to $7.77 Premarket After Novartis Agrees to Buy Co for up to $1.7 Bln

THOMSON REUTERS
·
30 Apr

Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal

Reuters
·
30 Apr

Novartis to Acquire Regulus Therapeutics

MT Newswires Live
·
30 Apr

BRIEF-Regulus Therapeutics Enters Into Agreement To Be Acquired By Novartis AG

Reuters
·
30 Apr

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

GlobeNewswire
·
30 Apr

Regulus Therapeutics Inc - Deal Valued up to $1.7 Billion With Contingent Value Right

THOMSON REUTERS
·
30 Apr

Regulus Therapeutics Enters Into Agreement to Be Acquired by Novartis Ag

THOMSON REUTERS
·
30 Apr